Not Signed In - Peregrine Pharmaceuticals Reports Positive Phase Ib Results For Its Targeted Immunotherapy Bavituximab In Chronic Hepatitis C Infection
Thu, 15 Feb 2007 08:00 AM EST
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today reported preliminary top-line results from a Phase lb study of its targeted immunotherapy bavituximab in patients with chronic HCV infection. [click link for full article] ...
Related Topics
- Hepatitis C
- Hepatitis B
- Hepatitis
- Hepatitis A
- Autoimmune Hepatitis
- Ear Infections
- Yeast Infections
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Infection (bladder)
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Infection (kidney)
- Vaginal Infections
- Hepatitis B Vaccine
- Urinary Tract Infections
- Urinary Tract Infection
- Chronic Fatigue Syndrome
- Chronic Pain
- Pain - Chronic
email this page
print this page
bookmark this page
feedback on this page
